[
  {
    "ts": "2025-12-11T11:59:00+00:00",
    "headline": "U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma",
    "summary": "PRINCETON, N.J., December 11, 2025--US FDA Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classic Hodgkin Lymphoma",
    "url": "https://finance.yahoo.com/news/u-food-drug-administration-fda-115900732.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "88cc6ed4-d196-34f9-9995-f6210b1030a3",
      "content": {
        "id": "88cc6ed4-d196-34f9-9995-f6210b1030a3",
        "contentType": "STORY",
        "title": "U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma",
        "description": "",
        "summary": "PRINCETON, N.J., December 11, 2025--US FDA Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classic Hodgkin Lymphoma",
        "pubDate": "2025-12-11T11:59:00Z",
        "displayTime": "2025-12-11T11:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/7df2d92dd0eefd370d0baf701e3c9671",
          "originalWidth": 1497,
          "originalHeight": 206,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EwyS5K4VWpLnsNZ453ZJ2g--~B/aD0yMDY7dz0xNDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/7df2d92dd0eefd370d0baf701e3c9671.cf.webp",
              "width": 1497,
              "height": 206,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/__efceiZ8DBsK6Sn60m.ww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7df2d92dd0eefd370d0baf701e3c9671.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/u-food-drug-administration-fda-115900732.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/u-food-drug-administration-fda-115900732.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T04:36:06+00:00",
    "headline": "3 Unpopular Stocks with Questionable Fundamentals",
    "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
    "url": "https://finance.yahoo.com/news/3-unpopular-stocks-questionable-fundamentals-043606875.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "ad9dddbf-e80c-37f1-a078-5e4a220ba4c6",
      "content": {
        "id": "ad9dddbf-e80c-37f1-a078-5e4a220ba4c6",
        "contentType": "STORY",
        "title": "3 Unpopular Stocks with Questionable Fundamentals",
        "description": "",
        "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
        "pubDate": "2025-12-11T04:36:06Z",
        "displayTime": "2025-12-11T04:36:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/bd01267adc63bb5f45458f264cb3d6a2",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "CROX Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DJFhQ1MfArNnd1Gtx6.TRw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/bd01267adc63bb5f45458f264cb3d6a2.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7ai0GlUxYTJUgFj.XF25nQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/bd01267adc63bb5f45458f264cb3d6a2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-unpopular-stocks-questionable-fundamentals-043606875.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-unpopular-stocks-questionable-fundamentals-043606875.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BFH"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CROX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T16:38:00+00:00",
    "headline": "Acute Lymphocytic Leukemia Market: Analysis and Forecast, 2025-2035",
    "summary": "The global acute lymphocytic leukemia (ALL) market is set for substantial growth from 2025 to 2035, fueled by advances in chemotherapy, targeted therapies, and immunotherapy. Particularly affecting children and aggressive in adults, ALL is increasingly treated with personalized medications like Tyrosine Kinase Inhibitors and CAR-T cell therapy, transforming patient outcomes. Despite challenges like high treatment costs and drug resistance, the demand for innovative combination therapies is risin",
    "url": "https://finance.yahoo.com/news/acute-lymphocytic-leukemia-market-analysis-163800268.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "b65d222a-b53c-3918-bffa-084ee579e664",
      "content": {
        "id": "b65d222a-b53c-3918-bffa-084ee579e664",
        "contentType": "STORY",
        "title": "Acute Lymphocytic Leukemia Market: Analysis and Forecast, 2025-2035",
        "description": "",
        "summary": "The global acute lymphocytic leukemia (ALL) market is set for substantial growth from 2025 to 2035, fueled by advances in chemotherapy, targeted therapies, and immunotherapy. Particularly affecting children and aggressive in adults, ALL is increasingly treated with personalized medications like Tyrosine Kinase Inhibitors and CAR-T cell therapy, transforming patient outcomes. Despite challenges like high treatment costs and drug resistance, the demand for innovative combination therapies is risin",
        "pubDate": "2025-12-11T16:38:00Z",
        "displayTime": "2025-12-11T16:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/acute-lymphocytic-leukemia-market-analysis-163800268.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/acute-lymphocytic-leukemia-market-analysis-163800268.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "NVS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]